Skip to main content
. 2009 Mar 20;100(5):813–820. doi: 10.1111/j.1349-7006.2009.01120.x

Figure 6.

Figure 6

Immunolocalization of phospho‐protein kinase B 2 (Akt2), phospho‐Akt substrate, transforming growth factor‐β receptor I (TGFβRI), and epidermal growth factor receptor (EGFR) in the glutathione S‐transferase placental form‐positive proliferative lesions generated after promotion by fenbendazole for 57 weeks. (a,b) Selective expression of phospho‐Akt2 in an adenoma (a) and in a carcinoma (b) in contrast to surrounding non‐tumor tissue. (c,d) An adenoma showing both cytoplasmic and membrane immunoreactivities (c), and a carcinoma showing predominantly cytoplasmic immunoreactivity (d) with the antibody against phospho‐Akt substrate. (e,f) Positive immunoreactivity of TGFβRI (e) and negative reactivity of EGFR (f) in an adenoma. Immunoreactivity in the same portion of the identical adenoma is presented in panels (a), (c), (e), and (f). (a), (b), (c), (e), (f) Bar = 100 µm (d) Bar = 50 µm. Ad, adenoma; Ca, carcinoma.